Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Bayer AG NA (BAYGn)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
26.90 -0.08    -0.28%
11:28:40 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DE000BAY0017 
WKN:  BAY001
  • Prev. Close: 26.90
  • Open: 27.09
  • Day's Range: 26.87 - 27.51
Bayer 26.90 -0.08 -0.28%

Bayer AG NA Company Profile

 
Get an in-depth profile of Bayer AG NA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

96931

Equity Type

ORD

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Contact Information

Address Kaiser-Wilhelm-Allee 1
Leverkusen, 51368
Germany
Phone 49 214 30 1
Fax -
Web www.bayer.com

Top Executives

Name Age Since Title
Norbert Winkeljohann 64 2018 Independent Chairman of Supervisory Board
Daniel Hartert 63 - Chairman of Executive Board - Bayer Business Services
Heike Hausfeld 57 2017 Vice Chairman of Supervisory Board
Ertharin Cousin 65 2019 Independent Member of the Supervisory Board
Paul M. L. Achleitner 66 2002 Member of Supervisory Board
Horst Baier 66 2020 Independent Member of Supervisory Board
Gunter Hilken 68 - Chairman of Executive Board - Currenta
Otmar D. Wiestler 67 2014 Independent Member of Supervisory Board
Frank Löllgen 62 2015 Member of Supervisory Board
Colleen A. Goggins 69 2017 Independent Member of Supervisory Board
Heinz Georg Webers 64 2022 Employee Representative Member of Supervisory Board
Simone Bagel-Trah 54 2014 Independent Member of Supervisory Board
Barbara Gansewendt 60 2022 Employee Representative Supervisory Board Member
André van Broich 53 2012 Member of Supervisory Board
Norbert W. Bischofberger 67 2017 Independent Member of Supervisory Board
Alberto Weisser 68 2021 Independent Supervisory Board Member
Andrea Sacher 42 2020 Member of Supervisory Board
Claudia Schade 45 2022 Employee Representative Supervisory Board Member
Francesco Grioli 51 2022 Employee Representative Member of the Supervisory Board
Yasmin Fahimi 56 2022 Employee Representative Member of Supervisory Board
Kimberly Mathisen 51 2022 Independent Member of the Supervisory Board
Michael Westmeier 51 2022 Employee Representative Member of the Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

BAYGn Comments

Write your thoughts about Bayer AG NA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alexander Zinchenko
Alexander Zinchenko Apr 20, 2024 12:31PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
still too high
Reply
0 0
Report
Luca ZeStonks
Luca ZeStonks Apr 17, 2024 7:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
STIFEL cut target price from 42 to 30 Euro. I changed my negative view and closed my positions and go long. ALWAYS do the opposite of what STIFEL recommends
Reply
5 0
Report
Crim Jamer
Crim Jamer Apr 17, 2024 7:05AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
played out well
Reply
0 0
Report
Luu Mrv
Luu Mrv Apr 15, 2024 2:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is not matter of any results ! is matter of the lawsuit! that's all.
Reply
0 1
Report
Ovidiu Ivan
Ovidiu Ivan Apr 15, 2024 11:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
it is a very poor company. to much debt. The price is good if you believe that the new CEO will put the company towards a good destination. At this price you can risk some money and speculate that is going to deliver some decent results in Q1
Reply
0 1
Report
Luca ZeStonks
Luca ZeStonks Apr 15, 2024 11:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
first 24, then 20 euro and then 15 euro. Then at 15 you can buy if you believe the company doesnt go bankrupt
Reply
0 0
Report
Luca ZeStonks
Luca ZeStonks Apr 11, 2024 10:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Poor longs getting knocked out again. 26 and then 24 follow
Reply
1 0
Report
amt hun
amt hun Mar 07, 2024 8:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I bet the Chinese and the Indian investors are piling up the shares like crazy at this price.
Reply
9 1
Report
Luca ZeStonks
Luca ZeStonks Mar 07, 2024 3:56AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Next knock out 25 then 24, then from July recovery
Reply
2 1
Report
Luca ZeStonks
Luca ZeStonks Mar 05, 2024 8:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
27 knock out coming soon
Reply
2 1
Report
Luca ZeStonks
Luca ZeStonks Mar 05, 2024 8:40AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
KNOCKED OUT BOOM
Reply
1 0
Report
Luu Mrv
Luu Mrv Mar 05, 2024 5:48AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
from ext week will rise over 30. ;)
Reply
0 2
Report
Luca ZeStonks
Luca ZeStonks Feb 29, 2024 8:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Next trial loss lets go to 24 euros
Reply
3 0
Report
ollie susnea
ollie susnea Feb 29, 2024 8:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
then I will buy
Reply
1 0
Report
amt hun
amt hun Feb 29, 2024 8:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
bayer is winning the overwhelming majority of the trials, but those don't make it to the news.
Reply
1 0
Report
Luca ZeStonks
Luca ZeStonks Feb 29, 2024 8:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
5k+ lawsuits to go
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email